Success Metrics

Active Trials
7(78%)

Phase Distribution

Ph phase_2
1
11%
Ph phase_1
4
44%
Ph phase_3
3
33%

Phase Distribution

4

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
4(50.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
3(37.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(8)
Other(1)

Detailed Status

Recruiting7
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 14 (50.0%)
Phase 21 (12.5%)
Phase 33 (37.5%)

Trials by Status

unknown111%
recruiting778%
not_yet_recruiting111%

Recent Activity

7 active trials
Showing 5 of 9
unknown

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

NCT07573215
not_yet_recruitingphase_1

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

NCT07756281
recruitingphase_3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

NCT06881784
recruitingphase_1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338
recruitingphase_1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

NCT06128551
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07573215

Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

Unknown
NCT07756281Phase 1

First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

Not Yet Recruiting
NCT06881784Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Recruiting
NCT07397338Phase 1

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Recruiting
NCT06128551Phase 1

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Recruiting
NCT07252232Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
NCT07492680Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Recruiting
NCT07491445Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
NCT07349537Phase 1

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Recruiting

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9